Levomefolic acid (INN) is the metabolite of folic acid (Vitamin B9) and it is a predominant active form of folate found in foods and in the blood circulation, accounting for 98% of folates in human plasma [A19276]. It is transported across the membranes including the blood-brain barrier into various tissues where it plays an essential role in the DNA synthesis, cysteine cycle and regulation of homocysteine, where it methylates homocysteine and forms methionine and tetrahydrofolate (THF). Levomefolate is approved as a food additive and is designated a GRAS (generally regarded as safe) compound [L773]. It is available commercially as a crystalline form of the calcium salt (Metafolin(R)), which has the stability required for use as a supplement [A19276]. Supplementation of levomefolic acid is desired over folic acid due to reduced potential for masking vitamin B12 deficiency symptoms.
Drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium
Chromagen
Prenate Elite
L-Methyl PNV DHA
Natal PNV
Quflora Pediatric Drops
LorMate
Vitafol Fe Plus
Tricare Prenatal DHA One With Folate
Livita Children
Poly-Vi-Flor
WesCap-PN DHA
Beyaz
OBTREX DHA Combo Pack
WellFola
L-Methylfolate Calcium
Obstetrix EC
EnLyte
PNV Tabs 20-1
Denovo
Levomefolate Calcium and Algal
PramLyte
Obstetrix DHA Combo Pack
Folene
MaxFe
Virt-PN Plus
Poly-VI-flor
Biopar delta-FORTE
Multi-Vit-Flor
Tri-Vi-Flor
Levomefolate Calcium, Pyridoxal 5-phosphate, Methylcobalamin and Schizochytrium DHA Oil
Davimet-M
WestGel DHA
Levomefolate Calcium, Cyanocobalamin and Pyridoxine Hydrochloride
Yasmin Plus
Prenate Mini
Sulfzix
Zatean-Pn
Hematron-AF
L-Methyl-MC
Menatrol
Indication
For the treatment and prevention of folate deficiency and for use as an antidote against folic acid antagonists. Contained in oral contraceptives to reduce the risk of neural tube defects arising from folic acid deficiency for pregnant women who conceived during use or shortly after the discontinuation of the product. Being studied for use as a treatment for cardiovascular diseases [A19273] and adjunct therapy for patients undergoing antidepressant pharmacotherapy [A19271, A19272].
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682